Displaying 1 - 20 of 35
FTC Submits Comment Supporting Proposed USPTO Terminal Disclaimer Rule
FTC Issues Policy Statement on Brand Pharmaceutical Manufacturers’ Improper Listing of Patents in the Food and Drug Administration’s ‘Orange Book’
In Re Bystolic Antitrust Litigation
FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market
FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices
Procedures for Oversight of the Horseracing Integrity and Safety Authority’s Annual Budget
FTC Approves Final Order Preserving Competition for Development and Marketing of Steroid Injectable Drug
Hikma Pharmaceuticals/Custopharm
As a condition of Hikma Pharmaceuticals PLC’s $375 million acquisition of generic drug services company Custopharm, Inc., the Federal Trade Commission required Custopharm’s parent company, private equity fund Water Street Healthcare Partners, LLC to retain and transfer Custopharm’s assets related to the corticosteroid drug triamcinolone acetonide, or TCA, to another company Water Street owns, Long Grove Pharmaceuticals, LLC. According to the complaint, absent a remedy, Hikma likely would have stopped developing its injectable TCA product, forestalling the increased price competition it would have brought to the market. Thus without this remedy, the acquisition likely would have harmed future competition in the U.S. market for injectable triamcinolone acetonide.
FTC to Ramp Up Enforcement Against Any Illegal Rebate Schemes, Bribes to Prescription Drug Middleman That Block Cheaper Drugs
Statement of Commissioner Alvaro M. Bedoya Regarding the Commission's Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products
FTC and Justice Department to Hold Two-Day Virtual Public Workshop Starting Tomorrow that Re-examines Antitrust Enforcement in the Pharmaceutical Industry
FTC Launches Inquiry Into Prescription Drug Middlemen Industry
FTC and Justice Department to Hold Two-Day Virtual Public Workshop Examining Antitrust Enforcement in the Pharmaceutical Industry
Federal Trade Commission Preserves Competition for Development and Marketing of Steroid Injectable Drug
ANI/Novitium; Analysis of Agreement Containing Consent Orders To Aid Public Comment
FTC Approves Final Order Imposing Conditions on Combination of Pfizer Inc.’s Upjohn and Mylan N.V.
Pfizer Inc. and Mylan N.V.; Analysis of Agreement Containing Consent Orders To Aid Public Comment
Displaying 1 - 20 of 35